Arca Biopharma files application for Covid-19 drug treatment
Westminster-based biotech company Arca Biopharma has submitted an Investigational New Drug application for Covid-19.
The application was filed under the Coronavirus Treatment Acceleration Program. The application will evaluate the use of one of Arca Biopharma's drugs, AB201, as a treatment for patients hospitalized with Covid-19.
The 13-employee Arca Biopharma typically focuses on genetically targeted therapie s for cardiovascular diseases. AB201 is believed to be effective with RNA viruses, which…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Jensen Werley Source Type: news
More News: Biotechnology | Cardiology | Cardiovascular | Coronavirus | COVID-19 | Genetics | Health Management | Heart | Investigational New Drugs | New Drug Applications | Pharmaceuticals